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Inhibition of β-Glucocerebrosidase 
Activity Preserves Motor Unit 
Integrity in a Mouse Model of 
Amyotrophic Lateral Sclerosis
Alexandre Henriques1,2,3, Mylene Huebecker4, Hélène Blasco5,6, Céline Keime7, Christian R. 
Andres5,6, Philippe Corcia5,8, David A. Priestman4, Frances M. Platt4, Michael Spedding3 & 
Jean-Philippe Loeffler1,2
Recent metabolomic reports connect dysregulation of glycosphingolipids, particularly ceramide 
and glucosylceramide, to neurodegeneration and to motor unit dismantling in amyotrophic lateral 
sclerosis at late disease stage. We report here altered levels of gangliosides in the cerebrospinal fluid 
of amyotrophic lateral sclerosis patients in early disease stage. Conduritol B epoxide is an inhibitor of 
acid beta-glucosidase, and lowers glucosylceramide degradation. Glucosylceramide is the precursor 
for all of the more complex glycosphingolipids. In SOD1G86R mice, an animal model of amyotrophic 
lateral sclerosis, conduritol B epoxide preserved ganglioside distribution at the neuromuscular junction, 
delayed disease onset, improved motor function and preserved motor neurons as well as neuromuscular 
junctions from degeneration. Conduritol B epoxide mitigated gene dysregulation in the spinal cord and 
restored the expression of genes involved in signal transduction and axonal elongation. Inhibition of 
acid beta-glucosidase promoted faster axonal elongation in an in vitro model of neuromuscular junctions 
and hastened recovery after peripheral nerve injury in wild type mice. Here, we provide evidence that 
glycosphingolipids play an important role in muscle innervation, which degenerates in amyotrophic 
lateral sclerosis from the early disease stage. This is a first proof of concept study showing that 
modulating the catabolism of glucosylceramide may be a therapeutic target for this devastating disease.
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease and the most common motor neuron 
disease among adults. ALS is characterized by a loss of upper motor neurons in the motor cortex and of lower 
motor neurons located in the brainstem and in the spinal cord. Gene mutations are associated with familial and 
sporadic forms of ALS. Most of the genetic forms of ALS are associated to mutations in genes encoding super-
oxide dismutase 1 (SOD1), TAR DNA binding protein of 43-kDa (TDP-43) and fused in sarcoma (FUS), or to 
hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9ORF72)1. The therapeutic options 
for ALS remain limited despite extensive preclinical and clinical research leading to more than 50 randomized 
clinical trials, a wide majority of them aiming to counteract directly the process of neurodegeneration2. Along 
with the loss of motor neurons, a metabolic pathology is present in ALS and affects the central nervous system 
and peripheral organs3. A high incidence of dyslipidemia and hypermetabolism is present in ALS patients4, 5. 
High LDL/HDL ratios or high body mass index are associated with better prognosis and slower disease progres-
sion6, 7. Pilot clinical trials suggest that nutritional diets enriched with lipids are beneficial for ALS patients in 
terms of survival and for preventing weight-loss8–10. The SOD1 mouse, a genetic model of ALS, is hypermetabolic, 
1Université de Strasbourg, UMR_S 1118, Fédération de Médecine Translationnelle, Strasbourg, France. 2INSERM, 
U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Strasbourg, France. 3Spedding Research 
Solutions SAS, Le Vesinet, France. 4Department of Pharmacology, University of Oxford, Oxford, UK. 5INSERM, 
Université François-Rabelais, U930, Neurogénétique et Neurométabolomique, Tours, France. 6CHRU de Tours, 
Laboratoire de Biochimie et de Biologie Moléculaire, Tours, France. 7IGBMC (Institut de Génétique et de Biologie 
Moléculaire et Cellulaire), INSERM, U964, CNRS, UMR7104, Université de Strasbourg, 67404, Illkirch, France. 8CHRU 
de Tours, Centre SLA, Tours, France. Correspondence and requests for materials should be addressed to J.-P.L. 
(email: loeffler@unistra.fr)
Received: 20 January 2017
Accepted: 26 May 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 5235  | DOI:10.1038/s41598-017-05313-0
and uses lipids preferentially over carbohydrates as nutrients11, and survives longer when fed with a high fat diet12. 
ALS is thus a disease with a major metabolic component.
Changes in levels of sphingolipids, particularly of glycosphingolipids, were recently described in the central 
nervous system of ALS patients at disease endpoint and in SOD1 mice at various disease stages13, 14. With the 
exception of asialo-GM1 and asiolo-GM2, gangliosides are a subset of glycosphingolipids containing three or 
more sugar moieties and one or more sialic acids. Conversion of ceramide into glucosylceramide (GlcCer) is the 
initial step for the de novo synthesis of all of the more complex glycosphingolipids, which takes place in the Golgi 
apparatus15. Gangliosides are present in tissues and body fluids, and are particularly enriched in the cell mem-
brane within the nervous system16, 17. The composition of brain gangliosides changes from simple (e.g. GM3) to 
complex gangliosides (e.g. GM1a) during neuronal development, and is associated with increased neurogenesis, 
synaptogenesis and axonal arborisation18, 19.
GM1a is one of the main gangliosides in the nervous system. The mature nervous system requires ganglio-
sides, including GM1a, in lipid rafts and at synapses for maintaining physiological functions. GM1a is anchored 
in the outer leaflet of the membrane by ceramide linked to five specific sugars which are exposed at the extracel-
lular surface, and can interact with the receptors of growth factors, such as BDNF20, 21. Guillain-Barré syndrome 
is caused by the presence of autoimmune antibodies which target complex gangliosides. Autoantibodies binding 
to GM1a or to GD1a at nodes of Ranvier and at the presynaptic part of neuromuscular junctions (NMJs) lead 
to acute motor axonal neuropathy, a sub-type of Guillain-Barré syndrome with severe motor axonal degener-
ation22, 23. GM1a is also located in the nuclear envelope, where it interacts with the sodium-calcium exchanger 
to potentiate calcium transfer and can regulate genes during neuronal development by binding to acetylated 
histones24, 25.
We have shown recently that NMJ integrity in SOD1G86R mice requires functional synthesis of glucosylceramide, 
the precursor of more complex glycosphingolipids, suggesting that they could be key modulators of ALS severity13, 14. 
Indeed, inhibition of GlcCer synthesis caused impaired nerve regeneration after peripheral nerve injury and was 
highly deleterious in SOD1G86R mice13, 14. The expression of ugcg, a gene encoding the enzyme catalysing the first 
step of glycosphingolipid synthesis, was strongly upregulated in muscle biopsies of ALS patients, independent of 
disease severity, suggesting a dysregulation in glycosphingolipid homeostasis in ALS at early disease stage.
Since inhibition of the synthesis of GlcCer delayed motor recovery in wild type mice and caused fragmenta-
tion of motor endplates in SOD1G86R mice, we reasoned that inhibition of β-glucocerebrosidase (GCase), which is 
responsible for the hydrolysis of GlcCer, may be beneficial in SOD1G86R mice. We thus used a well-characterised 
specific and covalent GCase inhibitor, conduritol B epoxide (CBE)26. High dose CBE (100 mg/kg/d) has been 
used to inhibit the lysosomal GCase almost completely in neonatal mice to induce a chemical model of Gaucher’s 
diseases with neuronal toxicity27, 28. However, low dose CBE (10 mg/kg/d) triggers partial inhibition, allowing 
residual activity and rapid wash-out with no reported toxicity in adult mice26, 28. We studied the metabolism of 
glycosphingolipids in ALS at early disease stage, in patients and in SOD1G86R mice, and its relation to the integrity 
of NMJs.
Results
Altered ganglioside expression is evident at disease onset in SOD1G86R mice and ALS patients. 
Gangliosides, particularly GM1a, are key structural components of the myelin sheath and also of lipid rafts at the 
cell surface. We sought to determine whether disease progression could be associated with loss of GM1a at the 
neuromuscular junctions (NMJs) in an animal model of ALS, the SOD1G86R mouse. The symptomatic phase of the 
disease starts at 95 days of age in this animal model of ALS. Symptoms include muscle weakness, mild locomotor 
impairments and muscle fibrillation detectable by electromyography. Symptoms progress towards skeletal muscle 
paralysis and atrophy, leading to death around 105 days of age.
Distribution of GM1a and other gangliosides was studied at the NMJs of SOD1G86R mice, using the cholera 
toxin subunit B (CTB), which is known to bind to gangliosides with highest affinity for GM1a29, 30.
CTB signal was detected close to the motor endplates in wild type controls (Fig. 1A). Most of the struc-
tures were localized in close proximity to the axonal proteins neurofilament-L and synaptophysin, which are 
found in motor axons innervating NMJs. CTB staining was detected close to the post-synaptic part of NMJs, 
where CTB-positive structures overlapped with clusters of acetylcholine receptors (Fig. 1A). Distribution of 
CTB-positive structures was further studied at the presynaptic and post-synaptic parts of NMJs in SOD1G86R 
mice. At 75 days of age, before disease onset, CTB staining was evident close to all NMJs and had a distribution 
pattern comparable to wild type mice. At 95 days of age, at disease onset, when the very first motor symptoms 
were detected, the majority of correctly innervated NMJs showed reduced axonal CTB staining in SOD1G86R mice 
(Fig. 1B and Supp. Fig. 1), indicating that ganglioside dysregulation is coincident with the loss of the NMJs, and 
may start before widespread denervation.
Cerebrospinal fluid plays a major role in the clearance of neuronal and axonal debri31. Individuals suffering 
from demyelinating diseases or from severe neuronal loss have increased sphingolipid content (e.g. sphingomye-
lin, ceramide and glycosphingolipids) in their cerebrospinal fluid32, 33. In an attempt to detect neuronal or axonal 
loss of gangliosides, we sought to quantify their levels in the cerebrospinal fluid of ALS patients at diagnosis 
and of individuals diagnosed with non-demyelinating neurological disorders. Although not significant, a trend 
for increased protein level was detected in the samples from ALS presented as compared to controls, which is 
often seen in neurodegenerative diseases34. GlcCer, and gangliosides from the a-series (GM1a and GD1a) and 
b-series (GD1b and GT1b) were identified by their sugar moieties using high performance liquid chromatog-
raphy (Table 1 and Supp. Fig. 2). The levels of other gangliosides were below the threshold for quantification. 
Levels of GlcCer and GM1a were both significantly increased in ALS patients. None of the levels of the glycos-
phingolipids correlated with the age at onset or BMI (data not shown). The severity of progression of the disease, 
determined by the loss of ALSFRS-R score per month, was available for 11 ALS patients. In this subset of patients, 
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the severity of the disease was positively correlated with the level of GM1a in the cerebrospinal fluid (Supp. Fig. 2), 
maybe indicating neuronal loss or elevated basal levels of GM1a, which could be detrimental for the prognosis of 
patients. Taken together, these results show that the homeostasis of gangliosides is dysregulated early on in ALS.
Figure 1. Loss of CTB staining at the NMJs in the tibialis anterior muscle of early symptomatic SOD1G86R mice. 
(A) Representative pictures of ganglioside distribution along motor axons, after staining with cholera toxin 
subunit B (CTB, green) and with neurofilament-L, synaptophysin and bungarotoxin (red). Scale bar = 50 µm. 
(B) Quantification showing the proportion of NMJs with normal cholera toxin subunit B (CTB) staining along 
motor axons in presymptomatic and early symptomatic SOD1G86R mice (B). WT 75d n = 5, SOD1 75d n = 5, 
WT 95d n = 5, SOD1 95d n = 6; ***p < 0.001. Mean ± SEM.
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Inhibition of GCase activity delays disease onset and improves motor functions in early symp-
tomatic SOD1G86R mice. Inhibition of GlcCer synthesis weakens NMJs and hastens disease progression 
in SOD1G86R mice13, 14. Here, we sought to prevent the hydrolysis of GlcCer by inhibiting β-glucocerebrosidase 
activity (GCase). We used conduritol B epoxide (CBE)26, known to bind to both the lysosomal and non-lysosomal 
forms of GCase and to inhibit their activity35. Initially, we showed that the CBE treatment (10 mg/kg/day) did not 
alter body mass and muscle strength of wild type mice (Fig. 2A,B). The treatment successfully inhibited GCase 
activity and increased total ganglioside levels, mainly through increased ganglioside GM1a in the spinal cord 
(Fig. 2A–E). Presymptomatic SOD1G86R mice and wild type littermates were then treated with CBE for 20 days. 
The treatment was terminated at the early disease stage, at 95 days of age, when SOD1G86R mice usually present 
muscle weakness and denervation.
Body mass, muscle strength and locomotion profiles were monitored to determine the onset of motor symp-
toms. No change in body weight was observed over the course of the disease after treatment (Fig. 2F). However, 
the onset of muscle strength loss was significantly delayed by 6 days in SOD1G86R mice treated with CBE com-
pared to the vehicle group (Fig. 2G). Automated gait analysis revealed that the locomotor profile of SOD1G86R 
mice at 95 days of age was characterized by reduced average speed, reduced stride length and paw swing, com-
pared to wild type littermates. CBE treatment prevented the development of locomotor impairments in SOD1G86R 
mice and improved speed and step cycles (Fig. 2H–L).
At 95 days of age, electromyography revealed that muscle fibrillation, a sign of muscle denervation, was less 
frequently detected in the gastrocnemius muscle of SOD1G86R mice upon CBE treatment, as compared to the vehi-
cle group (Fig. 3A). At this time point, neurodegeneration was detected in the lumbar spinal cord of SOD1G86R 
mice, and resulted in a 65% loss of large motor neurons as compared to wild type (Fig. 3B,C) and clear signs of 
denervation were present in tibialis muscle as only 60% of NMJs were fully innervated (Fig. 3D,E). Although still 
observed, loss of alpha-motor neurons was mitigated by CBE treatment of SOD1G86R mice. Moreover, the number 
of correctly innervated NMJs was significantly higher in SOD1G86R mice after CBE treatment as compared to the 
vehicle group (Fig. 3E), suggesting that CBE given before disease onset successfully delayed muscle denervation 
in SOD1G86R mice. Moreover, the treatment prevented loss of CTB-positive structures, potentially lipid rafts con-
taining GM1a and other gangliosides, at NMJs (Fig. 3F). Taken together, these data demonstrate that inhibition 
of GCase activity by CBE is able to modulate the pathophysiology of ALS and improves the integrity of motor 
units in SOD1G86R mice.
Inhibition of GCase activity modulates spinal transcriptome in early symptomatic SOD1G86R 
mice. At 95 days of age, sequencing of spinal messenger RNA identified a total of 761 significantly dysreg-
ulated genes in early symptomatic SOD1G86R mice when compared to wild type. The number of abnormalities 
found in SOD1G86R mice was strongly reduced after CBE treatment (Fig. 4A).
Comparison of transcriptomes from the SOD1 vehicle and SOD1 CBE groups revealed that the treatment 
had a significant effect on 51 genes (17 upregulated and 36 dowregulated). Most of these genes had readjusted 
expressions toward wild type levels (Fig. 4B). Over-representation analysis showed that CBE had an effect on the 
expression of genes associated with “cell cycle”, “hemostasis”, “RET signalling”, “IGF1R signalling cascade” and 
“axon guidance” (Supp. Table 1). Validation of RNA sequencing was performed by quantitative PCR for a subset 
of genes (Fig. 4C). Selected genes were (i) found to be dysregulated in SOD1G86R mice compared to wild type, 
(ii) modulated by CBE and (iii) were associated with relevant pathophysiological features of ALS, such as altered 
regulation of energy metabolism, inflammation, regulation of ubiquitin-protease system and excitotoxicity/glu-
tamatergic signalling.
The ASB5 gene was strongly dysregulated in the SOD1G86R mice. The function of ASB5 is not well character-
ized, particularly in the central nervous system. This protein interacts with proteins involved in the maturation of 
Items Neurological disorders ALS p-value
Cohort size 12 14
Female (%) 33.3 40
Male (%) 66.7 60
Age (years) 68.3 ± 1.4 70.3 ± 0.6 n.s.
ALSFRS-R N/A 39.9 ± 0.3 —
Site of onset (bulbar/spinal) N/A 5/9 —
CSF glucose (mmol/L) 3.8 ± 0 4.1 ± 0 n.s.
CSF protein (g/L) 0.44 ± 0.01 0.51 ± 0.02 n.s.
GlcCer 84.8 ± 1 98.9 ± 1.1 *
GM1a 83.9 ± 1.1 104.3 ± 2.3 *
GD1a 74.6 ± 1.8 88.2 ± 2.3 n.s.
GD1b 71.7 ± 1.7 97 ± 2.3 n.s.
GT1b 54 ± 2.3 66.8 ± 3.7 n.s
Table 1. Glycosphingolipid dysregulation in the cerebrospinal fluid of ALS patients. The characteristics and 
levels of glycosphingolipids of individuals diagnosed with non-ALS neurological disorders and ALS are shown. 
Glycosphingolipids are expressed as HPLC peak area/µl CSF, Mean ± SEM. *Corrected p-value < 0.05.
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ribosomes, the ribophorins, located in the endoplasmic reticulum, and with E3 ubiquitin ligase36. CBE treatment 
completely restored the expression of ASB5 to basal levels.
MRC1 and F13A1 are two genes coding for proteins that are markers for the M2 phenotype of microglia/
macrophage lineage37, 38. Upregulation of microglial/macrophage markers in SOD1G86R mice could be a sign of 
infiltration of peripheral macrophages or activation of microglia cells in symptomatic SOD1G86R mice. CBE treat-
ment had a significant correcting effect on the expression of both genes.
Slc25a27 is the gene coding for uncoupling protein 4, a mitochondrial protein associated with the regula-
tion of mitochondrial membrane potential. UCP4 activity contributes to the uptake of glucose in neurons and 
the reduction of reactive oxygen species. UCP4 activity is also associated with increased resistance to neuronal 
stress39. In SOD1G86R mice, UCP4 was downregulated, presumably because of altered energy metabolism in ALS3, 
and corrected upon CBE treatment.
ROR2, which was upregulated in SOD1G86R mice, is associated with regulation of synaptic plasticity but also 
participates in the transmission of glutamate signalling through GluN/NMDA receptors40. The upregulation of 
ROR2 could therefore be part of the glutamatergic stress present in ALS. CBE treatment prevented the upregula-
tion of ROR2 in SOD1G86R mice.
Figure 2. Pharmacological inhibition of GCase activity delays disease onset and improves motor functions in 
SOD1G86R mice. (A) Body mass evolution in wild type mice after 10 days of CBE treatment (n = 5/group). (B) 
Muscle strength of wild type mice after 10 days of CBE treatment (n = 5/group). (C) Total β-glucocerebrosidase 
activity measured in the spinal cord lysate of wild type mice (n = 5). (D,E) GlcCer (D) and gangliosides (E) 
levels in the spinal cord of wild type mice after CBE treatment (n = 5/group). (F) Body mass evolution in 
SOD1 and WT mice (n = 7 for WT groups, n = 12 for SOD1 veh and n = 14 for SOD1 CBE). (G) Kaplan-Meier 
showing time to onset of muscle strength loss in SOD1G86R mice (n = 12 for SOD1 veh and n = 14 for SOD1 
CBE, p < 0.02). (H–L) Catwalk analysis showing representative pattern of strides of symptomatic SOD1G86R 
mice (H), and average speed (I), stride length (J), paw swing (K) and stand index (L) in 95 days old mice. 
Mean ± SEM, *p < 0.05.
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DEPDC7 is a positive modulator of the NF-κB transcription factor and interacts with the CARMA proteins 
to the CBM Complex41. Due to the wide range of physiological processes regulated by NF-κB, a dysregulation 
of DEPDC7 could have repercussions on the activation of autophagy, inflammation, neuronal plasticity and cell 
survival42, 43. The strong upregulation of DEPDC7 by CBE treatment was confirmed by qPCR.
Figure 3. Pharmacological inhibition of GCase activity promotes neuroprotection in SOD1G86R mice. 
(A) Frequency of denervation in gastrocnemius muscle of SOD1G86R mice, at 95 days of age, detected by 
electromyography (n = 12, SOD1 veh; n = 13 SOD1 CBE). (B) Representative pictures of spinal motor neurons, 
after immunostaining with choline acetyl transferase (ChAT, red). Scale bar = 50 µm. (C) Quantification 
of cells located in the ventral horn of the spinal cord and having a size bigger than 400 µm2 (n = 10/group). 
(D) Representative pictures of fully innervated (left), partially innervated (middle) and denervated (right) 
neuromuscular junctions, after immunostaining with neurofilament and synaptophysin antibodies (green) and 
bungarotoxin (red), in tibialis anterior muscle. (E) Neuromuscular junction integrity in tibialis anterior muscle 
(n = 10/group). (F) Distribution of CTB signal at neuromuscular junctions in tibialis anterior muscle (n = 10/
group). Mean ± SEM, *p < 0.05; **p < 0.005; ***p < 0.001.
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CBE stimulates maturation of in vitro motor units and promotes recovery after sciatic nerve 
injury in vivo. Inhibition of GlcCer synthesis delays axonal regeneration after peripheral nerve injury13, 
suggesting that GlcCer is involved in the regenerative process of motor axons and in the maturation of NMJs. 
We hypothesized that increasing levels of GlcCer using CBE would have beneficial effects on the maturation of 
NMJs. CBE was added to a co-culture of spinal cord explants and myoblast cells, used as an in vitro model of 
motor units44. Levels of glycosphingolipids were upregulated upon CBE-treatment, in a dose-dependent manner 
for GlcCer and for the main neuronal ganglioside, GM1a (Fig. 5A). A modest effect was observed on the pre-
dominant muscle ganglioside GM3. As expected, CTB staining was localized predominantly with axons in the 
co-culture (Fig. 5B). Three weeks after differentiation, we observed a higher incidence of functional maturation of 
spinal explants (Fig. 5C) and greater total area of innervation per functional spinal explant (Fig. 5D) with a dose 
of 10 µM of CBE. A higher dose of CBE (100 µM) had no significant effect on these parameters compared to the 
control group receiving the vehicle. The effect of CBE on the regulation of gene expression during neuronal dif-
ferentiation was studied in the neuronal PC12 cell line. CBE treatment led to a strong inhibition of GCase activity, 
almost complete at 100 µM of CBE (94% of inhibition), or moderate at lower doses of CBE, 1 µM and 10 µM, as 
shown by the presence of residual activity (Fig. 5E). The expression of the transcription factor atf3 and atf4 and 
the axonal proteins neurofilament-M and p75 were significantly upregulated by CBE at 1 μM and 10 μM. High 
dose of CBE had no significant effect on the expression of atf3 and atf4 (Fig. 5F), suggesting that residual GCase 
activity is required for the mediation of axonal plasticity. Taken together, these results suggest a direct role for 
glycosphingolipids in the control of axonal plasticity and regeneration and could explain the positive effect seen 
on muscle innervation in SOD1G86R mice after CBE treatment.
Next, we sought to determine whether CBE treatment could support motor recovery after nerve injury in 
wild type mice. CBE was administered on a daily basis (10 mg/kg/day), from 2 days prior injury until the end of 
the study, 12 days after injury. Recovery of motor function was assessed by monitoring the time to toe spread-
ing, interpreted as the first visible signs of re-innervation, and by general locomotion and motor strength. In 
the vehicle group, toe spreading was observed 8 days after nerve injury, and recovery of muscle strength started 
10 days after injury. At the study endpoint, 12 days after the injury, the locomotor profile of the vehicle group 
showed a strong reduction in the contact area and reduced hind limb step cycle of ipsilateral paw. Toe spread-
ing and recovery of muscle strength occurred significantly faster by 2–4 days after CBE treatment (Fig. 5G,H), 
Figure 4. CBE treatment corrects transcriptomic dysregulation in spinal cord of SOD1G86R mice. (A) Venn 
diagrams showing gene dysregulations in the spinal cord in SOD1G86R mice receiving the vehicle (red circles) 
or the CBE (blue circles), and compared to wild type. (B) Hierarchical clustering performed with genes 
significantly regulated by CBE in SOD1G86R mice in the spinal cord (black: wild type; blue: SOD1G86R -CBE; 
dark red: SOD1G86R veh). (C) Expression levels determined by quantitative PCR for selected genes. Data are 
presented as Mean +/− SEM; *p-value < 0.05.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 5235  | DOI:10.1038/s41598-017-05313-0
Figure 5. Inhibition of GlcCer degradation by CBE improves in vitro axonal plasticity and in vivo nerve 
regeneration. (A) Quantification of glycosphingolipids in the co-culture of muscle and spinal cord explants after 
CBE treatment. (B) Representative pictures for the distribution of neurofilament-L (red) and the cholera toxin 
subunit B (CTB, green) in the co-culture. Arrows indicate CTB-positive structures along an axon. (C) Given 
is the number of functional explants per culture plate identified by the presence of contraction of muscle fibres 
(n = 6). (D) Total area of innervation of functional explants after differentiation (n = 8/group). (E) Total GCase 
activity in PC12 cells after treatment with various doses of CBE (n = 3/group). (F) Transcriptional regulation 
of markers for neuronal differentiation in PC12 (n = 3/group). (G) Kaplan-Meier showing time to observable 
toe spreading after sciatic nerve injury (n = 7/group). (H) Muscle strength of ipsilateral hind paws, after 
sciatic nerve injury (n = 7/group). (I) Representative pictures for the areas of hind limb paws in contact with 
the ground. (J,K) Maximal contact area (J) and step cycle (K) of hind paws as determined by automated gait 
analysis. Mean +/− SEM; *p < 0.05; **p < 0.01.
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and the locomotor profile of the injured paw was closer to the contralateral side for contact area (Fig. 5I,J) and 
hindlimb step cycle compared to the vehicle group (Fig. 5K). Experimental denervation, induced by peripheral 
nerve injury, led to the severe loss of CTB-positive structures binding at the presynaptic part of the NMJs on the 
ipsilateral side of injury in tibialis anterior muscle, presumably due to the Wallerian degeneration or to lack of 
mature myelin sheaths. A partial loss of CTB staining was also observed at the post-synaptic part of the NMJ after 
denervation (Supp. Fig. 3). In all, partial inhibition of the GCase activity and increase in glycosphingolipids were 
beneficial for the regeneration of motor axons post-injury.
Discussion
Complex lipids participate in stability of neuromuscular junctions. Case reports from the 1980’s 
reported the presence of antibodies targeting gangliosides, and particularly GM1a, in the serum of some ALS 
patients45, 46 along with the presence of unusual gangliosides in post-mortem brains and spinal cords47, 48, empha-
sizing a role for glycosphingolipids in ALS. Administration of gangliosides was clinically tested in ALS patients 
with preliminary either positive or inconclusive effects, especially since these studies were underpowered49–51. 
Lipid microdomains are membrane areas enriched in cholesterol, sphingomyelin and glycosphingolipids (e.g. 
GM1a). These domains participate in cell-cell interaction52 and are key for the trafficking and clustering of ace-
tylcholine receptors at the NMJs53–55. Depletion of cholesterol and sphingolipids from lipid rafts prevents the 
formation of acetylcholine receptors upon agrin application56, 57.
Acute motor axonal neuropathy, a subtype of Guillain-Barré disease, is due to the presence of autoimmune 
antibodies targeting GM1a at the motor endplate or at the nodes of Ranvier, causing specific dismantling of motor 
units with no influence on sensory functions. These autoimmune antibodies may prevent the interaction between 
the sugar headgroup of gangliosides with surrounding molecules. Indeed, the ganglioside GM1a interacts with 
neurotrophin receptors58, such as TrkA and modulates ions flux across membranes through the activation of Na+ 
-K+- ATPase exchanger19.
In the present study, we used the cholera toxin subunit B (CTB), which binds to gangliosides with highest 
affinity for GM1a29, 30. We show a loss of CTB staining in the immediate vicinity of motor axons and of muscle 
acetylcholine receptors, in early symptomatic SOD1G86R mice, reinforcing the possibility that loss of gangliosides 
like GM1a may be a critical factor for muscle denervation in ALS.
Clinical relevance of GCase inhibition for ALS. Modulators of sphingolipid levels have not been clin-
ically tested in ALS and a therapy based on GCase activity appears attractive. We and others have reported 
increased gangliosides in ALS patients and SOD1 mice13, 14, and deleterious effects after administration of inhibi-
tors of GlcCer synthesis for the integrity of neuromuscular junctions in SOD1G86R mice13 and on their survival14. 
In addition, these studies have demonstrated that inhibition of GlcCer synthesis is also highly detrimental for 
axonal regeneration after peripheral nerve injury13. We propose that increases in glycosphingolipid levels seen 
in ALS patients and SOD1 mice are part of an innate and physiological, but late, response to neurodegeneration.
We show here that glycosphingolipids are intimately involved in innervation in normal mice, and reduced at 
neuromuscular junctions in the early stages of disease progression of SOD1G86R mice.
We also report for the first time a beneficial effect of an inhibitor of GCase activity in an animal model of ALS. 
Indeed, partial inhibition of GCase activity in SOD1G86R mice, with a modest dose of CBE, resulted in preserved 
motor functions, higher counts of motor neurons and preserved NMJs. In addition, the treatment was able to pro-
mote faster axonal elongation in vitro and in vivo, confirming that partial inhibition of GCase activity, associated 
with an increase in other glycosphingolipids, is beneficial for motor units.
Our study was designed using a low dose of CBE, which is a potent inhibitor of the lysosomal GCase with mod-
erate but significant inhibition of the non-lysosomal GCase35. Gaucher disease is caused by homozygous muta-
tions in GBA1, which are an important risk factor for Parkinson disease59, and mutations in the non-lysosomal 
GBA2 have been linked to hereditary spastic paraplegia60 and spastic ataxia61.The covalent binding of CBE to 
GCases may easily lead to full inhibition of total GCase activity if given in high enough dose, as shown in our in 
vitro assay. CBE has been used to induce a chemical model of Gaucher disease in neonatal mice26. However, the 
toxicity of CBE is very widely variable depending on mouse strain62. Even though lysosomal GCase is inhibited 
by 90–95% at a daily dose of 25 mg/kg/day starting at neonatal age, there is no correlation between lifespan and 
residual enzyme activity. A/J mice die within 25 days with severe motor defects, whereas BTBR + Ttftf mice live 
for more than 200 days. FVB mice, the background strain in our SOD1G86R mice, live for about 120 days. A wash-
out of 3 days following CBE treatment has been reported to be long enough to restore GCase activity26, showing 
the importance of partial inhibition. Optimal dosage for long-term administration of GCase inhibitors should be 
therefore carefully determined.
Gaucher disease patients have elevated plasma levels of GlcCer and gangliosiodes63, 64, suggesting that the 
GlcCer accumulated in the lysosome can get back to the early Golgi and be converted into lactosylceramide 
which can then be sialylated to GM3, a precursor of GM1a. As we saw an elevation of GM1a in the SOD1 mouse 
spinal cord after CBE treatment, it is possible that it is generated from GlcCer via the biosynthetic pathway in the 
Golgi.
The increase of GM1a could account for the beneficial effects of GCase inhibition in SOD1G86R mice. Changes 
in gangliosides have also been described in other neurodegenerative diseases. Brains of Alzheimer’s disease 
patients have low levels of gangliosides65, 66 and GM1a distribution is abnormal, particularly in the human 
dentate gyrus67. Loss of GM1a was also documented close to nigral dopaminergic neurons in Parkinson’s dis-
ease patients68 and associated with reduced neurotrophic signalling69. Conversely, direct injection of GM1a in 
Parkinson’s disease patients stabilized disease progression in a pilot trial70. In a randomized and double-blind trial, 
direct administration of GM1a reduced motor symptoms while treatment discontinuation worsened symptoms 
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emphasizing a direct effect71. Synthesis of GM1a is increased in cultured cortical neurons after glutamate-induced 
stress and reduce excitotoxicity72 and intracerebroventricular infusion of GM3 improved survival in SOD1 G93A 
mice14. Interestingly, a recent study reports the beneficial effect of IgM against GM1a in SOD1 mouse models. 
The authors proposed that the IgM treatment triggers neuroprotective cell signalling after the membrane reor-
ganization of GM1a73.
Degeneration of NMJs precedes motor neuron loss in ALS74 and axonal transport is deficient in SOD1(G93A) 
mice before disease onset75. In our study, CTB staining was markedly reduced at innervated neuromuscular junc-
tions of early symptomatic SOD1G86R mice. Loss of gangliosides at distal motor axons may be an early pathologi-
cal event in ALS. CTB staining was fully restored after CBE treatment, indicating that this is an effect on complex 
gangliosides and on innervation. Despite a 50% reduction of total GCase activity after low dose CBE treatment, 
we saw a 10% increase in gangliosides in the spinal cord, in line with previous reports28, 76. Neuroprotection 
detected after GCase inhibition could therefore be independent of spinal gangliosides. Differential expression 
of genes was previously reported in the transcriptome of isolated motor neurons77 and whole spinal cord78–80 of 
SOD1G86R mice. Our RNA sequencing analysis revealed beneficial effect of CBE on the global spinal transcrip-
tome of SOD1G86R mice. Almost two thirds of the transcriptional dysregulations present at early symptomatic 
stage were not found after treatment. Notably, GCase inhibition by CBE prevented the deregulation of genes 
involved in molecular pathways known to participate to disease progression, including cell signalling, energy 
metabolism, neuroinflammation and axonal guidance. Importantly, our data support an effect of CBE on axonal 
plasticity in SOD1G86R mice, with higher rate of innervated NMJs. We demonstrated an effect of CBE, most likely 
direct, on axonal regeneration in vivo on wild type mice, and in vitro on the expression profile of key transcription 
factors for axonal elongation and on building functional neuromuscular junctions. These experiments do not 
allow a definition of causalities but encourage further work on potential benefit of this approach.
To conclude, we now have evidence whereby inhibition of GCase preserves innervation and slows down dis-
ease progression in SOD1G86R mice, whereas inhibition of GlcCer synthesis has exactly the reverse effects13, 14. In 
all, partial inhibition of GCase activity leading to increased levels of GlcCer and downstream glycosphingolipids 
is beneficial for the regeneration of motor axons post-injury in wild type mice and delays the degeneration of 
motor neurons and neuromuscular junctions in an animal model of ALS.
Method
Patients. A case–control study was performed to study the distribution of glycosphingolipids in the cerebro-
spinal fluid samples of 14 ALS patients and 12 control subjects. Individuals were recruited at the ALS centre in 
Tours, France. Cerebrospinal fluid was collected during routine lumbar puncture at the time of diagnosis from 
individuals with ALS, or from individuals showing motor dysfunctions. Controls were diagnosed with Parkinson’s 
disease (n = 1), cerebellar ataxia (n = 1), dementia (n = 1), spinal stenosis (n = 1), epilepsy (n = 1), axonal neurop-
athy (n = 4), and motor dysfunctions of unclear origin but unrelated to ALS (n = 3). CSF samples from age- and 
gender-matched healthy controls were inaccessible at the time of the study. All patients gave informed consent 
and the protocol was approved by the ethical committee of Tours. All human-related methods were performed in 
accordance with the relevant guidelines and regulations. Standard biochemical tests were performed, including 
bacteriology test, and glucose and protein quantifications.
Animal experiments. Experiments followed current European Union regulations (Directive 2010/63/EU) 
and were performed by authorized investigators (A67–402 to A.H.), after approval by the ethic committee of the 
University of Strasbourg and by the ministry of higher education and research (APAFIS#662, APAFIS#2255).
SOD1G86R mice. FVB/N female mice, overexpressing the SOD1(G86R) protein, were maintained in our animal 
facility at 23 °C with a 12 hours light/dark cycle. Mice had access to water and to regular A04 rodent chow ad libi-
tum. GlcCer degradation was inhibited with conduritol B epoxide (CBE, 10 mg/kg/day, Cayman chemical, Ann 
Arbor, USA). CBE (10 mg/kg/d) or the vehicle (NaCl 4%) was given by intraperitoneal injection. The treatment 
started at 75 days of age and stopped at 95 days of age. Wild type littermates served as controls. Mice were sacri-
ficed by intraperitoneal injection with ketamine chlorohydrate (100 mg/kg) and xylazine (5 mg/kg) and intracar-
dially perfused with PBS at 4 °C.
Sciatic Nerve Injury. Peripheral nerve injury was performed in order to induce muscle denervation and axonal 
regeneration. Wild type mice were anesthetized with ketamine chlorohydrate (100 mg/kg) and xylazine (5 mg/
kg). The sciatic nerve was exposed at mid-thigh level and lesioned with fine forceps for 30 s. The skin incision was 
sutured, and mice were allowed to recover. The hind limb, contralateral to the lesion, served as control. Mice were 
treated with CBE (10 mg/kg/d) for 12 days, starting the day before surgery. Mice were followed on a daily basis. 
Mice were sacrificed by intraperitoneal injection with ketamine chlorohydrate (100 mg/kg) and xylazine (5 mg/
kg) and intracardially perfused with PBS at 4 °C.
Assessment of motor functions. Body mass and muscle strength (mean of three tests, grip test, Bioseb, Chaville, 
France) were analysed on a daily basis. Onset of muscle strength loss was defined as a drop of more than 10% of 
the mouse maximal strength.
The locomotor profiles of mice were analysed with a catwalk device (Noldus). Mice were habituated to the 
device at 85 days of age for SOD1G86R mice, or before surgery for mice subjected to sciatic nerve crush. The loco-
motor profiles were recorded at least three times per mice. The software CatWalk XT (version 10.5, Noldus) was 
use to analyse video recording and to determine the average speed (average speed of an animal’s body during 
the whole run), paw swing (duration in seconds of the step corresponding to the absence of contact between a 
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paw and the glass plate), stride length (distance between successive placements of the same paw), limb step cycle 
(duration between two consecutive initial contacts of the same paw), max contact area (surface area of the print 
at Max contact) and stand index were measured.
Electromyography: After anaesthesia as indicated above, muscle fibre potentials were detected using a elec-
tromyography apparatus (Dantec, Les Ulis, France), in accordance with the recommendation of the American 
Association of Electrodiagnostic Medicine. A concentric electromyography-needle electrode (no. 9013S0011, 
diameter 0.3 mm; Medtronic, Minneapolis, MN) was inserted in the gastrocnemius. Ground signal was deter-
mined with a monopolar needle electrode (no. 9013R0312, diameter 0.3 mm; Medtronic) inserted into the tail of 
the animal. Presence of fibrillations was investigated in three different muscle regions. Only spontaneous activity 
with peak-to-peak amplitude of at least 50 μV was considered to be significant.
Cell culture. PC12. PC12 cells (Sigma-Aldrich) were cultured in 24-well plates with Dubelcco modified 
Eagle medium, 10% horse serum, 5% foetal calf serum, 1% penicillin/streptamicyine, and 1% Fungizone. At 70% 
of confluence, differentiation was initiated in DMEM, 1% horse serum, 1% foetal bovin serum, 1% penicillin/
streptamicyine, 1% fungizone and nerve growth factor (100 ng/mL). CBE treatments started the first day of dif-
ferentiation. Mediums were renewed every other day. Twelve days after differentiation, the cells were collected, 
pelleted by centrifugation and stored at −80 °C until further analysis.
Co-culture of spinal cord explants and myoblasts. The rat spinal cord-human muscle co-culture was performed 
as described previously81. Briefly, human myoblast was grown in a F14 medium (Invitrogen, Cergy-Pontoise, 
France), with glutamine 2 mM, insulin, epidermal growth factor, basic Fibroblast growth factor, foetal bovine 
serum 10% (FBS, Hyclone) and an antibiotic-antimycotic mixture (Gibco). Spinal cord explants of 14-day-old 
Wistar rat embryos (Janvier, Le Genest-St-IsIe, France) were placed on the muscle monolayer. The co-cultures 
were maintained in MEM (Gibco) supplemented with 25% medium 199 (Gibco), 5% FBD, 1 pg/ml insulin and 
antibiotic-antimycotic mixture. CBE treatment was initiated when the spinal cord explant were added to the 
muscle monolayer and was renewed twice a week for 3 weeks, until the end of the experiments. Innervation areas 
were identified by the presence of contraction of muscle fibres, highlighted under microscopy and analysed with 
ImageJ82.
Histology. For histological analysis, tissues were fixed 1 hour in paraformaldehyde 4% and stored in PBS at 
4 °C or snap frozen in isopentane and stored at −80 °C until further use.
Spinal cord. Lumbar segments L2-L3 fixed in paraformaldehyde 4% were used for studying the number of 
motor neurons innervating tibialis anterior muscle83. Coronal sections 40 µm thick from L2-L3 spinal segment 
were realized with a vibratome and were stained with an anti-choline acetylcholine transferase (1/100, Millipore, 
France) and an alexa594 conjugated goat (1/200, Jackson) antibodies. All neurons located in the ventral horn, that 
were >400 µm2 in size and ChAT positive were considered as alpha motor neurons. Six sections of spinal cord that 
were apart over a length of 0.24 mm were counted. Photomicrographs were taken with a Nikon microscope and 
cell area of motor neurons was measured with NIS Element 4.0 (Nikon).
Muscle bundles. Tibialis anterior muscle samples fixed in paraformaldehyde 4% were dissected into bun-
dles under a binocular microscope. Bundles were collected from at least three different parts of the mus-
cle. Acetylcholine receptors in the postsynaptic apparatus of NMJs were labelled with rhodamine-conjugated 
α-bungarotoxin (Sigma–Aldrich). Immunofluorescent labelling of nerve terminals was performed with a 
rabbit polyclonal anti-synaptophysin antibody (1/200, Abcam, Cambridge, UK) and with a rabbit polyclonal 
anti-neurofilament L antibody (1/200, Abcam, Cambridge, UK). For assessing NMJs integrity, an Alexa-488 con-
jugated goat anti-rabbit was used as secondary antibody (1/500, Jackson). Neuromuscular junction integrity was 
assessed by studying the colocalization of synaptophysin/neurofilament and α-bungarotoxin signal.
Effect of CBE on gangliosides at the neuromuscular junction was determined by labelling muscle bundles from 
tibialis anterior with cholera toxin sub-unit beta (CTB) coupled with an Alexa488 dye (1/200, ThermoFisher), and 
the rhodamine-conjugated α-bungarotoxin (1/500, Sigma-Aldrich). An Alexa-594 conjugated goat anti-rabbit 
was used as secondary antibody (1/500, Jackson). Only NMJs showing a normal axonal staining were considered 
for assessing CTB signal.
Wild type NMJs usually shows several dozens of CTB positive structures. CTB signal was considered as nor-
mal when at least 10 CTB positive structures were detected along presynaptic motor axons of innervated NMJs. 
Photomicrographs were taken with an ApoTom 2 (Zeiss) microscope and analysed with ZEN 2 (blue edition).
Coronal muscle sections. Twenty-micrometre sections were obtained by cutting isopentane fresh-frozen 
tibialis anterior muscle perpendicular to the muscle axis with a cryostat at −20 °C (Leica, Nanterre, France). 
Acetylcholine receptors in the postsynaptic apparatus of neuromuscular junctions were labelled with 
rhodamine-conjugated α-bungarotoxin (Sigma–Aldrich). Gangliosides distribution was labelled with the chol-
era toxin sub-unit beta coupled with an Alexa488 dye (1/200, ThermoFisher). Photomicrographs were taken with 
a Nikon microscope and analysed with NIS Element 4.0 (Nikon).
Normal phase high performance liquid chromatography. Glycosphingolipids were studied in the 
cerebrospinal fluid of ALS patients, in mouse tissues and cells after CBE treatment. GlcCer and downstream 
gangliosides were analysed as described previously13. Tissues were homogenized in water using an Ultraturax 
T25 probe homogenizer (IKA, Germany). Lipids from tissue homogenates were extracted with chloroform and 
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methanol. The glycosphingolipids were then further purified using solid-phase C18 columns (Telos, Kinesis, 
UK). After elution, the glycosphingolipids fractions were split in half, dried down under nitrogen at 42 °C and 
treated with either Cerezyme® (Genzyme, Cambridge, MA) to obtain glucose from GlcCer or ceramide gly-
canase (prepared in house from the medicinal leech Hirudo medicinalis/verbena) to obtain oligosaccharides from 
other glycosphingolipids. The liberated glucose and free glycans were then fluorescently-labelled with anthranillic 
acid (2-AA). To remove excess free label, samples were separated in DPA-6S SPE columns (Supelco, PA, USA). 
Purified 2AA-labeled glucose and 2AA-labeled oligosaccharides were separated and quantified by normal-phase 
high-performance liquid chromatography as previously described by Neville and colleagues84. The solid phase 
used was a 4.6 × 250 mm TSK gel-Amide 80 column (Anachem, Luton, UK). The HPLC system consisted of a 
Waters Alliance 2695 separations module and an in-line Waters 2475 multi λ-fluorescence detector set at 360 nm 
(excitation) and 425 nm (emission).
β-glucosidase activity. Total β-glucosidase activity was assayed using the β-Glucosidase Activity Assay Kit 
(MAK129, Sigma). Dried tissues were lysed with a TissuLyser (Qiagen, CA) and suspended in ice-cold PBS. After 
centrifugation (14000 g for 10 min at 4 °C), the supernatants were transferred to new tubes and stored at −80 °C. 
Enzymatic reactions were carried out in KPi buffer (60 mM, pH 5.5) with p-NPG for 20 minutes at 37 °C. Final 
absorbance was measured at 405 nm.
Analysis of spinal transcriptome. RNA sequencing. Frozen samples of spinal cord were homogenised 
using a TissuLyser (Qiagen, CA). Extraction of total RNA was performed using the RNeasy Plus Universal 
Tissue kit (Qiagen) accordingly to manufacturer recommendations. RNA quality was assessed with BioAnalyser 
(Agilent). Libraries of template molecules suitable for high throughput DNA sequencing were created using the 
TruSeq™ RNA Sample Preparation v2 Kit. Briefly, mRNA were purified from 600 ng of total RNA using poly-T 
oligo-attached magnetic beads and fragmented using divalent cations at 94 °C for 8 min. The cleaved mRNA 
fragments were reverse transcribed to cDNA using random primers then the second strand of the cDNA was 
synthesized using DNA Polymerase I and RNase H. The double stranded cDNA fragments were blunted using 
T4 DNA polymerase, Klenow DNA polymerase and T4 PNK. A single ‘A’ nucleotide was added to the 3′ ends 
of the blunt DNA fragments using a Klenow fragment (3′ to 5′ exo minus) enzyme. The cDNA fragments were 
ligated to double stranded adapters using T4 DNA Ligase. The ligated products were enriched by PCR ampli-
fication (30 s at 98 °C; [10 s at 98 °C, 30 s at 60 °C, 30 s at 72 °C] × 12 cycles; 5 min at 72 °C). Then surplus PCR 
primers were removed by purification using AMPure XP beads (Agencourt Biosciences, Fullerton, CA, USA). 
The libraries were loaded in a flow cell and clusters were generated in the Cbot and sequenced in an Illumina 
Hiseq 2500 sequencer as single-end 50 base reads. Image analysis and base calling were performed using RTA 
1.18.61 and CASAVA 1.8.2. Reads were mapped onto mm10 assembly of mouse genome using Tophat v2.0.1485. 
Quantification of gene expression was performed using HTSeq v0.6.186 and Ensembl release 81 database. After 
normalization, statistical analysis for differential gene expression has been performed using BRB-arrayTools 
v4.4.1, developed by Dr. Richard Simon and the BRB-ArrayTools Development Team. Difference among groups 
was assessed with ANOVA for fixed model and considered significant with a FDR set at 0.1, and after post-hoc 
analysis with the Tukey’s Honest Significant differences method and p value below 0.05. Heat map clustering 
was performed using JMP 11.0.0, with the Ward method applied to the normalized read counts of genes whose 
expression was significantly modulated upon CBE treatment. The colour code represents the level of expres-
sion of the genes (red: high level; black: medium level; green: low level). Gene ontology was performed using 
ConsensusPathwayDB87, 88 and the Reactom database89, 90.
Quantitative PCR. Gene expression was assessed on a CFX96 using SYBR green Supermix reagent (BioRad) 
according to manufacturer’s instructions. Relative quantification of each gene was determined using the Biorad 
software and normalized to the normalization factor generated from the reference genes (Pol2, TBP and 18S).
Statistics
Experiments were performed by experimenters blinded for genotype and treatment identities, and the diag-
nosis of the patients. Data was expressed as the mean ± SEM and were analysed with PRISM 6.0b (GraphPad, 
San Diego, CA). Normality was assessed with Kolmogorov-Smirnov test or D’Agostino and Pearson. Two-tailed 
Student’s t test was used to compare two groups, and ANOVA followed by two-tailed Fisher’s LSD test was applied 
to compare more than two groups. If required, correction for multiple comparisons was performed using the 
Holm-Sidak method. Times to events were analysed with Log-rank test. Differences with p-values < 0.05 were 
considered significant.
Dataset availability statement. All data generated or analysed during this study are included in this 
published article (and its Supplementary Information Files).
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